Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2013 Feb 1;123(2):563-5. doi: 10.1172/JCI67460. Epub 2013 Jan 25.

B4 androgen ablation: attacking the prostate cancer stem cell.

Author information

  • 1University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 6302, Ann Arbor, Michigan 48109, USA. mwicha@umich.edu


There is increasing evidence that prostate cancers in rodent models and in men contain a cellular subpopulation that displays stem cell properties. These prostate cancer stem cells (PCSCs) lack androgen receptor expression and are increased in castration-resistant disease. In this issue of the JCI, a study from Yoshioka et al. demonstrates that PCSCs are regulated by a pathway in which α6β4 integrin amplifies signaling through ErbB2 and c-Met receptors. Targeting this pathway provides a novel therapeutic strategy for hormone refractory prostate cancer.

Comment on

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Write to the Help Desk